Previous 10 | Next 10 |
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that AJ Joshi, MD, Chief Medic...
Atara Biotherapeutics, Inc. (ATRA) Q3 2022 Results Conference Call November 08, 2022 04:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations and Finance Dr. Pascal Touchon - President and Chief Executive Officer Dr. Jakob Dupont - ...
Atara Biotherapeutics press release ( NASDAQ: ATRA ): Q3 GAAP EPS of -$0.82 misses by $0.03 . Revenue of $4.46M (-16.9% Y/Y) beats by $0.72M . Cash, equivalents and short-term investments as of September 30, 2022 totaled $265.4 million, as compared to $331.3 mi...
Ebvallo TM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Biomarker Imaging Data Show Less Brain Atrophy and Possible Remyelination in Patients Achieving Confirmed Disability Improvement in Progressive MS ...
Live Conference Call and Webcast at 4:30 p.m. EST Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi...
Sustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up Patients T reated with ATA188 that Achieved CDI Demonstrate Significantly Less Brain Atrophy in Longitudi...
Penny Stocks To Buy Now? Are you looking for penny stocks to buy now? If your answer is “yes,” you’re not alone. But before you dive headfirst into something someone on Reddit posted, you’ll want to make sure to do a few things first. For starters, find the t...
A committee of the European Medicines Agency ( EMA ) recommended the approval of Atara Biotherapeutics ( NASDAQ: ATRA ) and Pierre Fabre's Ebvallo as monotherapy to treat patients two years of age and older with relapsed or refractory Epstein‑Barr...
Ebvallo TM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European Commission Approval Expected in Q4 2022 Atara Biotherapeutics, Inc...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...